
Claims

1. A liquid pharmaceutical composition for oral administration comprising a bradykinin (BK) B2 receptor antagonist having a chemical structure according to Formula 1, or a stereoisomer, salt or solvate thereof:



(Formula 1)

wherein R is deuterium or hydrogen;
wherein the BK B2 receptor antagonist is dissolved in a liquid vehicle comprising propylene glycol monocaprylate, polyoxyl castor oil, and propylene glycol.

2. The liquid pharmaceutical composition of claim 1, wherein the BK B2 receptor antagonist is a compound according to Formula 1, or a salt or solvate thereof, wherein R is deuterium.

3. The liquid pharmaceutical composition of claim 1 or 2, wherein the amount of propylene glycol monocaprylate in the liquid vehicle is about 40-60 wt.%, based on the weight of the liquid vehicle.

4. The liquid pharmaceutical composition of any one of the preceding claims, wherein the amount of polyoxyl castor oil in the liquid vehicle is about 30-50 wt.%, based on the weight of the liquid vehicle.

5. The liquid pharmaceutical composition of any one of the preceding claims, wherein the amount of propylene glycol is about 2.5-15 wt.%, based on the weight of the liquid vehicle.

6. The liquid pharmaceutical composition of any one of the preceding claims, wherein the propylene glycol monocaprylate is a propylene glycol monocaprylate type II (USP/NF).

7. The liquid pharmaceutical composition of any one of the preceding claims, wherein the polyoxyl castor oil is a polyoxyl 40 hydrogenated castor oil (USP/NF).

8. The liquid pharmaceutical composition of any one of the preceding claims, wherein the content of propylene glycol monocaprylate is about 50 wt.%, the content of polyoxyl castor oil is about 40 wt.%, and the content of propylene glycol is about 10 wt.%, based on the combined weight of propylene glycol monocaprylate, polyoxyl castor oil, and propylene glycol in the liquid vehicle.

9. The liquid pharmaceutical composition of any one of the preceding claims, exhibiting a content of the BK B2 receptor antagonist in the range from about 5 mg to about 100 mg per g, such as from about 5 mg to about 65 mg per g, or such as from about 20 mg to 70 mg per g, of the liquid pharmaceutical composition.

10. The liquid pharmaceutical composition of any one of the preceding claims, essentially consisting of:

(a) based on the total weight of the liquid pharmaceutical composition, about 0.5 to 6.5 wt.%, such as 5 wt.%, of a compound according to Formula 1, or a stereoisomer, salt or solvate thereof, wherein R is deuterium;

(b) based on the total weight of the liquid pharmaceutical composition, about 93.5 to 99.5 wt.% of a liquid vehicle, said liquid vehicle essentially consisting of:

(i) about 50 parts (in weight) of propylene glycol monocaprylate, such as propylene glycol monocaprylate type II (USP/NF);

(ii) about 40 parts (in weight) of polyoxyl castor oil, such as 40 hydrogenated castor oil (USP/NF);

(iii) about 5 to 10 parts (in weight) of propylene glycol; and

optionally (iv) up to about 5 parts (in weight) of water;

and optionally

(c) the balance being one or more further excipients dissolved or dispersed in the liquid vehicle.

11. A capsule for oral administration, comprising the liquid pharmaceutical composition of any one of the preceding claims.

12. The capsule of claim 11, wherein the capsule is a soft capsule.

13. The soft capsule of claim 12, comprising a capsule wall which comprises gelatine, water, and at least one plasticiser selected from propylene glycol, glycerol, sorbitol, sorbitan, sorbitol-based plasticiser mixtures, or any combinations thereof.

14. The liquid pharmaceutical composition of any one of the claims 1 to 10, or the capsule of any one of the claims 11 to 13, for use in the acute or chronic treatment of a subject suffering from a disease or condition responsive to BK B2 receptor modulation.

15. The liquid pharmaceutical composition for use according to claim 14, or the capsule for use according to claim 14, wherein the disease or condition responsive to BK B2 receptor modulation is edema, such as hereditary angioedema.

16. Use of the liquid pharmaceutical composition of any one of the claims 1 to 10, or of the capsule of any one of the claims 11 to 13, in the manufacture of a medicament for treating or preventing a disease or condition that is responsive to BK B2 receptor modulation.

17. The use of claim 16, wherein the disease or condition that is responsive to BK B2 receptor modulation is edema, such as hereditary angioedema.